drugset

Drugs / IcoSema

Follow last change Jul 2025 re-read 2 minutes ago

IcoSema

also known as NNC0148-0287sema

Other / unclassified

Developed for: type 2 diabetes mellitus
Investigated by: Novo Nordisk A/S

Trials 4 · a red edge is where a trial was stopped

today NCT06269107 · Ph 3 NCT05435677 · Ph 1 NCT05352815 · Ph 3 NCT03789578 · Ph 1

20192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT05435677	Jun 2022 → Apr 2023	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT03789578	Jan → Oct 2019	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 32 trials
Phase 3	NCT06269107	Feb 2024 → May 2025	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT05352815	Jun 2022 → Mar 2024	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2024-01-08	Novo Nordisk A/S	COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes novonordisk.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

Field	Value	Cited text
Known as	IcoSema	“IcoSema is being developed as a subcutaneous once-weekly fixed-ratio combination of the once-weekly basal insulin icodec and the once-weekly glucagon-like peptide-1 receptor...” PMID 39488821 ↗ Nov 2024 3 NCT06269107 ↗ NCT05352815 ↗ NCT05435677 ↗
Known as	NNC0148-0287sema	“Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).” NCT03789578 ↗
Modality	Other / unclassified	“IcoSema is a once‑weekly combination therapy of basal insulin icodec [icodec] and semaglutide (a GLP‑1 analogue) currently in development.” PMID 40482671 ↗ Jun 2025
Route	Subcutaneous	“Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.” NCT05352815 ↗